Trifunctional NK cell engagers (NKCEs), targeting two activating receptors, NKp46 and CD16, on NK cells and a tumor antigen on cancer cells trigger tumor cell destruction and this approach was superior to therapeutic antibodies both in vivo and in vitro [89]. Here, NCR1 is linked to neoplasm.